Cytokine Biomarkers of Exacerbations in Sputum From Patients With Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae232 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Sonia Budroni und 12 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Siena, Italy. Hauptthemen laut MEDLINE: Biomarkers, Cytokines, Pulmonary Disease, Chronic Obstructive, Sputum. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals SA.
Themen: COPD
Abstract (Originalsprache)
Background
We determined the relationships between cytokine expression in sputum and clinical data to characterize and understand chronic obstructive pulmonary disease (COPD) exacerbations in people with COPD.
Methods
We measured 30 cytokines in 936 sputum samples, collected at stable state and exacerbation visits from 99 participants in the Acute Exacerbation and Respiratory InfectionS in COPD (AERIS) study (ClinicalTrials.gov NCT01360398). We determined their longitudinal expression and examined differential expression based on disease status or exacerbation type.
Results
Of the cytokines, 17 were suitable for analysis. As for disease states, in exacerbation sputum samples, interleukin (IL) 17A, tumor necrosis factor alpha (TNF-α), IL-1β, and IL-10 were significantly increased compared to stable state sputum samples, but a logistic mixed model could not predict disease state. As for exacerbation types, bacteria-associated exacerbations showed higher expression of IL-17A, TNF-α, IL-1β, and IL-1α. IL-1α, IL-1β, and TNF-α were identified as suitable biomarkers for bacteria-associated exacerbation. Bacteria-associated exacerbations also formed a cluster separate from other exacerbation types in principal component analysis.
Conclusions
Measurement of cytokines in sputum from COPD patients could help identify bacteria-associated exacerbations based on increased concentrations of IL-1α, IL-1β, or TNF-α. This finding may provide a point-of-care assessment to distinguish a bacterial exacerbation of COPD from other exacerbation types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK, Siena, Italy.
- GSK, Wavre, Belgium.
- GSK Vaccines Institute for Global Health, Siena, Italy.
- GSK, Rixensart, Belgium.
- Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton.
- National Institute for Health Research Southampton Biomedical Research Centre, Southampton Centre for Biomedical Research, Southampton General Hospital, Southampton, United Kingdom.
ORCID-Profile: Silvia Rossi Paccani
Förderung
- GlaxoSmithKline Biologicals SA
Zitieren
APA
Budroni, S., Taccone, M., Stella, M., Aprea, S., Schiavetti, F., Bardelli, M., Lambert, C., Rondini, S., Weynants, V., Contorni, M., Wilkinson, T. M. A., Brazzoli, M., & Rossi Paccani, S. (2024). Cytokine Biomarkers of Exacerbations in Sputum From Patients With Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae232
Vancouver
Budroni S, Taccone M, Stella M, Aprea S, Schiavetti F, Bardelli M, et al. Cytokine Biomarkers of Exacerbations in Sputum From Patients With Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae232
BibTeX
@article{Budroni2024,
author = {Budroni, Sonia and Taccone, Marianna and Stella, Maria and Aprea, Susanna and Schiavetti, Francesca and Bardelli, Monia and Lambert, Christophe and Rondini, Simona and Weynants, Vincent and Contorni, Mario and Wilkinson, Tom M A and Brazzoli, Michela and Rossi Paccani, Silvia},
title = {Cytokine Biomarkers of Exacerbations in Sputum From Patients With Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae232}
}
EUVIMED